Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beam Therapeutics (BEAM) Free Cash Flow (2019 - 2025)

Beam Therapeutics (BEAM) has disclosed Free Cash Flow for 7 consecutive years, with -$73.3 million as the latest value for Q4 2025.

  • On a quarterly basis, Free Cash Flow fell 2.98% to -$73.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$346.4 million, a 0.49% change, with the full-year FY2025 number at -$346.4 million, changed 0.49% from a year prior.
  • Free Cash Flow was -$73.3 million for Q4 2025 at Beam Therapeutics, up from -$86.5 million in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of $203.2 million in Q1 2022 to a low of -$115.8 million in Q1 2023.
  • A 5-year average of -$50.8 million and a median of -$78.5 million in 2022 define the central range for Free Cash Flow.
  • Biggest YoY gain for Free Cash Flow was 505.91% in 2022; the steepest drop was 571.22% in 2022.
  • Beam Therapeutics' Free Cash Flow stood at -$11.5 million in 2021, then tumbled by 571.22% to -$77.5 million in 2022, then soared by 233.67% to $103.5 million in 2023, then tumbled by 168.79% to -$71.2 million in 2024, then fell by 2.98% to -$73.3 million in 2025.
  • Per Business Quant, the three most recent readings for BEAM's Free Cash Flow are -$73.3 million (Q4 2025), -$86.5 million (Q3 2025), and -$79.6 million (Q2 2025).